Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers

Cancer Science

Volumn 100, Issue 7, 2009, Pages 1326-1334

  Shigematsu, Yoshiki ^a   Hanagiri, Takeshi ^a   Kuroda, Koji ^a   Baba, Tetsuro ^a   Mizukami, Makiko ^a   Ichiki, Yoshinobu ^a   Yasuda, Manabu ^a   Takenoyama, Mitsuhiro ^a   Sugio, Kenji ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANCER ANTIBODY; GENE X PROTEIN; IMMUNOGLOBULIN G; INTRAFLAGELLAR TRANSPORT 88 HOMOLOG; MESSENGER RNA; STRESS INDUCED PHOSPHOPROTEIN 1 HOMOLOGY AND U BOX CONTAINING PROTEIN 1; THROMBOSPONDIN 2; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN DETECTION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA LIBRARY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE PLAQUE ASSAY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RECOMBINANT EXPRESSION CLONING METHOD; SCID MOUSE; SEROLOGY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR ENGRAFTMENT;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; B-LYMPHOCYTE SUBSETS; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MESOTHELIOMA; MICE; MICE, SCID; MIDDLE AGED; TRANSPLANTATION, HETEROLOGOUS;

EID: 67449098379     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01181.x     Document Type: Article

References (46)

1. Peto J, Hodgson JT, Matthews FE et al. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995; 345: 535-9.
2. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999; 79: 666-72.
3. Statistics and Information Department Labour and Welfare of Japan. Vital Statistics of Japan 2003. Tokyo: Health and Welfare, Statistics Association, 2003.
4. Marinaccio A, Scarselli A, Binazzi A et al. Asbestos related diseases in Italy: An integrated approach to identify unexpected professional or environmental exposure risks at municipal level. Int Arch Occup Environ Health. 2008; 81: 993-1001.
5. Maule MM, Magnani C, Dalmasso P, Mirabelli D, Merletti F, Biggeri A. Modeling mesothelioma risk associated with environmental asbestos exposure. Environ Health Perspect. 2007; 115: 1066-71.
6. Ruffie P, Feld R, Minkin S et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol. 1989; 7: 1157-68.
7. Chailleux E, Dabouis G, Pioche D et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest. 1988; 93: 159-62.
8. Adams VI, Unni KK, Muhm JR et al. Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer. 1986; 58: 1540-51.
9. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg. 1999; 117: 54-65.
10. Mizukami M, Hanagiri T, Baba T et al. Identification of tumor associated antigens recognized by IgG from tumor-infiltrating B cells of lung cancer: Correlation between Ab titer of the patient's sera and the clinical course. Cancer Sci. 2005; 96: 882-8.
11. Mizukami M, Hanagiri T, Shigematsu Y et al. Effect of IgG produced by tumor-infiltrating B lymphocytes on lung tumor growth. Anticancer Res. 2006; 26: 1827-32.
12. Mizukami M, Hanagiri T, Yasuda M et al. Antitumor effect of antibody against a SEREX-defined antigen (UOEH-LC-1) on lung cancer xenotransplanted into severe combined immunodeficiency mice. Cancer Res. 2007; 1: 8351-7.
13. Yasuda M, Takenoyama M, Obata Y et al. Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer. Cancer Res. 2002; 62: 1751-6.
14. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995; 108: 895-7.
15. Sugaya M, Takenoyama M, Osaki T et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest. 2002; 122: 1282-288.
16. Yasumoto K, Manabe H, Nomoto K, Inokuchi K. Antibody specific for lung cancer cells detected in sera of patients with bronchogenic carcinoma. Gann. 1983; 74: 595-601.
17. Sikora K, Alderson T, Ellis J et al. Human hybridomas from patients with malignant disease. Br J Cancer. 1983; 47: 135-45.
18. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med. 1998; 187: 1163-7.
19. Punt CJ, Barbuto JA, Zhang H et al. Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes. Cancer Immunol Immunother. 1994; 38: 225-32.
20. Imahayashi S, Ichiyoshi Y, Yoshino I et al. Tumor-infiltrating B-cell derived IgG recognizes tumor components in human lung cancer. Cancer Invest. 2000; 18: 530-6.
21. Eichler EE, Lu F, Shen Y et al. Duplication of a gene-rich cluster between 16p11.1 and Xq28: A novel pericentromeric-directed mechanism for paralogous genome evolution. Hum Mol Genet. 1996; 5: 899-912.
22. Horvath JE, Viggiano L, Loftus BJ et al. Molecular structure and evolution of an alpha satellite/non-alpha satellite junction at 16p11. Hum Mol Genet. 2000; 9: 113-23.
23. Lawler J, Detmar M. Tumor progression: The effects of thrombospondin-1 and -2. Int J Biochem Cell Biol. 2004; 36: 1038-45.
24. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol. 2004; 36: 961-8.
25. Bornstein P, Agah A, Kyriakides TR. The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int J Biochem Cell Biol. 2004; 36: 1115-25.
26. Frazier WA. Thrombospondin: A modular adhesive glycoprotein of platelets and nucleated cells. J Cell Biol. 1987; 105: 625-32.
27. Hennessy SW, Frazier BA, Kim DD et al. Complete thrombospondin mRNA sequence includes potential regulatory sites in the 3′ untranslated region. J Cell Biol. 1989; 108: 729-36.
28. LaBell TL, Byers PH. Sequence and characterization of the complete human thrombospondin 2 cDNA: Potential regulatory role for the 3′ untranslated region. Genomics. 1993; 17: 225-9.
29. Oyama M, Kozuka-Hata H, Suzuki Y, Semba K, Yamamoto T, Sugano S. Diversity of translation start sites may define increased complexity of the human short ORFeome. Mol Cell Proteomics. 2007; 6: 1000-6.
30. Stoneley M, Willis AE. Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression. Oncogene. 2004; 23: 3200-7.
31. Grossfeld GD, Ginsberg DA, Stein JP et al. Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst. 1997; 89: 219-27.
32. Roth JJ, Reiver DM, Granick MS, Rothman VL, Nicosia RF, Tuszynski GP. Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteineglycine (CSVTCG) receptor of thrombospondin-1 in breast tumors. Histol Histopathol. 1997; 12: 1013-18.
33. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res. 1994; 85: 1045-9.
34. Ohta Y, Endo Y, Tanaka M et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res. 1996; 2: 1411-16.
35. Scanlan MJ, Chen YT, Williamson B et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer. 1998; 29: 652-8.
36. Kampinga HH, Kanon B, Salomons FA, Kabakov AE, Patterson C. Overexpression of the cochaperone CHIP enhances Hsp70-dependent folding activity in mammalian cells. Mol Cell Biol. 2003; 23: 4948-58.
37. Veenu T, Amjad A, Rajiv B, Uttam P. CHIP chaperones wild type p53 tumor suppressor protein. J Biol Chem. 2007; 28: 28 441-54.
38. Schrick JJ, Onuchic LF, Reeders ST et al. Characterization of the human homologue of the mouse Tg737 candidate polycystic kidney disease gene. Hum Mol Genet. 1995; 4: 559-67.
39. Contreras G, Mercado A, Pardo V, Vaamonde CA. Nephrotic syndrome in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1995; 6: 1354-9.
40. Sakamoto K, Suzuki H, Jojima T et al. Membranous glomerulonephritis associated with diffuse malignant pleural mesothelioma: Report of a case. Surg Today. 2000; 30: 1124-6.
41. Galesic K, Bozic B, Heinzl R et al. Pleural mesothelioma and membranous nephropathy. Nephron. 2000; 84: 71-4.
42. Ho M, Hassan R, Zhang J et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res. 2005; 11: 3814-20.
43. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003; 16: 192-7.
44. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008; 44: 46-53.
45. Hassan R, Ebel W, Routhier EL et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007; 19: 20-9.
46. Robinson C, Callow M, Stevenson S et al. Serologic responses in patients with malignant mesothelioma evidence for both public and private specificities. Am J Respir Cell Mol Biol. 2000; 22: 550-6.